The researchers behind the early-stage work, published in JCI Insight , are exploring whether kisspeptin can ultimately be used to treat men with common psychosexual disorders - sexual problems which are psychological in origin such as low libido. The team are now hoping to perform trials in patients with low sexual desire.
The team have previously shown that kisspeptin can enhance how the body processes sexual arousal but have now discovered a boosting effect of kisspeptin in human attraction brain pathways. Attraction is a fundamental process that triggers onward sexual arousal, sexual activity and often reproduction.
In a trial involving 33 heterosexual men, using MRI brain scanning, the team found that kisspeptin triggered greater activation in attraction pathways in the brain when smelling female perfume and when viewing female faces, compared to the placebo.
Dr. Alexander Comninos, Honorary Clinical Senior Lecturer at Imperial College London, Consultant Endocrinologist at Imperial College Healthcare NHS Trust and co-senior author of the study, said:
Psychosexual disorders have a major detrimental impact on wellbeing and can be highly distressing not only to those affected but also their partners. Despite the high numbers of people with these disorders,there are currently limited treatment options. Our study shows that kisspeptin can boost brain activity related to attraction and intriguingly this boosting effect is even greater in men with a low sexual quality of life.
This builds on our previous work that identified a role for kisspeptin in sexual arousal. Now we have found that kisspeptin may actually enhance the processing of smell and facial attraction, which are often the first steps to sexual arousal. We hope our growing understanding of how kisspeptin boosts parts of the brain involved in attraction and arousal can ultimately lead to new ways of treating people affected. However, we still have a long way to go."
Professor Waljit Dhillo, NIHR Research Professor in Endocrinology & Metabolism at Imperial College London and co-senior author of the study, added:
Attraction is usually the first step to sexual arousal and it's encouraging to see that kisspeptin can also boost brain activity relating to this. This new finding helps us further understand the brain activity of people with psychosexual disorders which could lead to therapeutic targets." Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology